Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus

Expert Opinion on Biological Therapy
Theocharis KoufakisKalliopi Kotsa

Abstract

Early short-term insulin treatment (STIT), defined as insulin administration shortly after diabetes diagnosis for only a brief period of time, is an alternative concept, aiming to entirely revise the perspective of type 2 diabetes (T2DM) management. Areas covered: The present review intends to summarize what is already known regarding early STIT in T2DM and highlight questions and dilemmas from the clinician's point of view, with a discourse on future research agenda. Expert opinion: STIT has the potential to modify the natural history of T2DM, resulting in improved drug-free remission rates by favorably affecting the underlying pathophysiology of the disease. Existing data in the field manifest significant weaknesses, mainly being the small number of trials and patients included, the lack of control groups in most studies and the wide heterogeneity between study designs and explored outcomes, which limit definitive conclusions. Therefore, before such a therapeutic strategy is incorporated into daily practice, important issues require further clarification by future trials. These issues include the optimal time point for the intervention, the ideal insulin type, the identification of patients being most likely to benefit, the S...Continue Reading

References

May 22, 1976·British Medical Journal·R C TurnerE Harris
Dec 28, 2002·Diabetes Care·Saul GenuthUNKNOWN American Diabetes Association
Apr 28, 2004·Diabetes Care·Edmond A RyanClarissa Wallace
Aug 3, 2005·The Journal of Clinical Investigation·Paresh DandonaAhmad Aljada
Nov 25, 2005·Diabetes·Marc Y DonathManfred Reinecke
Feb 20, 2007·The American Journal of Cardiology·Paresh DandonaPriya Mohanty
May 11, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·M A IhnatA Ceriello
Sep 2, 2008·Lancet·J Hans DeVriesJoost B Hoekstra
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Mayer B Davidson
Sep 16, 2009·International Journal of Clinical Practice. Supplement·T Kunt, F J Snoek
Oct 24, 2009·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Nov 13, 2009·Diabetes Care·Luigi F Meneghini
Jun 18, 2011·Postgraduate Medicine·Kevin D Niswender
Jun 13, 2012·The New England Journal of Medicine·Hertzel C GersteinSalim Yusuf
Jun 23, 2012·Diabetes Care·Lindsay B HarrisonIldiko Lingvay
Jun 22, 2013·Diabetes Technology & Therapeutics·David R Owens
Aug 2, 2013·Diabetes Care·Itamar Raz, Ofri Mosenzon
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Caroline Kaercher KramerRavi Retnakaran
Sep 10, 2014·Diabetes/metabolism Research and Reviews·Jianping WengJeong-Taek Woo
Dec 17, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·C M SteinR Retnakaran
Jul 1, 2015·International Journal of Obesity : Journal of the International Association for the Study of Obesity·S SkovsøJ J Holst
Nov 26, 2015·The Nursing Clinics of North America·Lucy Mays
Jul 22, 2016·Diabetes Care·Markolf HanefeldFrank Pistrosch
Aug 10, 2016·Journal of Diabetes Research·A SchaschkowE Maillard
Mar 16, 2017·Trends in Cardiovascular Medicine·Matthew H SecrestKristian B Filion
Dec 9, 2017·Diabetes & Metabolism·S Feldman-BillardUNKNOWN Standards for screeningand surveillance of ocular complications in people with diabetes SFD study group

❮ Previous
Next ❯

Citations

Aug 27, 2019·Journal of Diabetes·Theocharis KoufakisKalliopi Kotsa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Aaron P SchulmanFrancesco Rubino
Expert Opinion on Pharmacotherapy
Niki KatsikiDimitri P Mikhailidis
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
J Sánchez-CovisaB G Verheggen
© 2022 Meta ULC. All rights reserved